Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 11, 2009, Pages 1302-1309

  Loftus Jr , Edward V ^a   Johnson, Scott J ^b   Yu, Andrew P ^b   Wu, Eric Q ^b   Chao, Jingdong ^c   Mulani, Parvez M ^c  

^a MAYO CLINIC   (United States)

^b ANALYSIS GROUP   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Adalimumab; Cost effectiveness; Crohns disease; Tumor necrosis factor antagonist; Utility

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CROHN DISEASE; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG UTILIZATION; HOSPITALIZATION COST; HUMAN; MAINTENANCE THERAPY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REMISSION; SENSITIVITY ANALYSIS; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; COST-BENEFIT ANALYSIS; CROHN DISEASE; DRUG COSTS; EPIDEMIOLOGIC METHODS; FEMALE; GASTROINTESTINAL AGENTS; GREAT BRITAIN; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; REMISSION INDUCTION; STATE MEDICINE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 70350164003     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32832a8d71     Document Type: Article

References (36)

1. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007; 369:1627-1640.
2. Silverstein MD, Loftus EV, Sandborn WJ, Tremaine WJ, Feagan BG, Nietert PJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999; 117:49-57.
3. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369:1641-1657.
4. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004; 126:1504-1517.
5. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995; 30:699-706.
6. Canavan C, Abrams KR, Hawthorne B, Mayberry JF. Long-term prognosis in Crohn's disease: an epidemiological study of patients diagnosed more than years ago in Cardiff. Aliment Pharmacol Ther 2007; 25:59-65.
7. Canavan C, Abrams KR, Mayberry JF. Meta-analysis: mortality in Crohn's disease. Aliment Pharmacol Ther 2007; 25:861-870.
8. Fonager K, Sorensen HT, Olsen J. Change in incidence of Crohn's disease and ulcerative colitis in Denmark. A study based on the National Registry of Patients, 1981-1992. Int J Epidemiol 1997; 26:1003-1008.
9. Makharia GK. Rising incidence and prevalence of Crohn's disease in Asia: is it apparent or real? J Gastroenterol Hepatol 2006; 21:929-931.
10. Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J. The costs of Crohn's disease in the United States and other Western countries: a systematic review. Curr Med Res Opin 2008; 24:319-328.
11. Cohen RD, Larson LR, Roth JM, Becker RV, Mummert LL. The cost of hospitalization in Crohn's disease. Am J Gastroenterol 2000; 95:524-530.
12. Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol 1992; 14:318-327.
13. Humira [package insert]. Abbott Park, Illinois: Abbott Laboratories; 2008. Available at http://www.rxabbott.com/pdf/humira.pdf. [Accessed 6 May 2008]
14. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132:52-65.
15. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130:323-333.quiz 591.
16. NICE pharmacoeconomic modeling reference guidelines. See, for instance, http://www.nice.org.uk/niceMedia/pdf/GuidelinesManualChapter8.pdf. [Last accessed 1 March 2009]
17. Guidance on the use of infliximab for Crohn's disease. In: Technology appraisal guidance No. 40. London, UK: National Institute for Clinical Excellence; 2002. pp. 1-21.
18. Colombel J-F, Sandborn WJ, Rutgeerts P, Kamm M, Yu AP, Wu EQ, et al. Comparison of two adalimumab treatment schedule strategies for moderateto- severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol (in press).
19. Curtis L, Netten A. Inflation indices, unit costs of health and social care 2006. Kent, UK: Personal Social Services Research Unit; 2006. pp. 197-198. Available at http://www.pssru.ac.uk. [Accessed 17 May 2008]
20. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53:1471-1478.
21. Gregor J, McDonald J, Klar N, Wall R, Atkinson K, Lamba B, et al. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis 1997; 3:265-276.
22. Loftus E, Feagan B, Chen N, et al. Risk of crohn's disease-related hospitalization in patients receiving long-term adalimumab therapy: 3-year data from charm and ADHERE. Presented at the Fourth Congress of the European Crohn's & Colitis Organisation, 5-7 February 2009, Hamburg, Germany.
23. Annual Survey of Hours and Earnings (ASHE). United Kingdom: Office for National Statistics, 2006. Available at http://www.statistics.gov.uk/ StatBase/Product.asp?vlnk = 13101. [Accessed 12 June 2007]
24. Briggs A, Sculpher M, Claxton K. Decision modeling for health economic evaluation. New York: Oxford University Press; 2006.
25. Jaisson-Hot I, Flourie B, Descos L, Colin C. Management for severe Crohn's disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care 2004; 20:274-279.
26. Marshall J, Blackhouse G, Goeree R, Brazier N, Irvine E, Faulkner L, et al. Infliximab for the treatment of Crohn's disease: a systematic review and cost-utility analysis. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2002. Technology report no 24. Available at: http://cadth.ca/index.php/en/publication/315. [Accessed 9 September 2008]
27. NICE Guidance Document. Available at http://www.nice.org.uk/guidance/ index.jsp?action= byId&o = 11727. [Accessed 31 January 312009]
28. Eddy D. Bringing health economic modeling to the 21st century. Value Health 2006; 9:168-178.
29. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008; 135:1493-1499.
30. Rutgeerts P, Feagan B, Lichtenstein G, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126:402-413. (Pubitemid 38182297)
31. Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, et al. CDP571 Crohn's Disease Study Group. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001; 120:1330-1338.
32. Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, et al. A randomized placebo-controlled trial of humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001; 121:268-274.
33. Hommes DW, Mikhajlova TL, Stoinov S, Stimac D, Vucelic B, Lonovics J, et al. Fontolizumab. A humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006; 55:1131-1137.
34. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, et al. Natalizumab Pan-European Study Group. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348:24-32.
35. Sands BE, Winston BD, Salzberg B, Safdi M, Barish C, Wruble L, et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 2002; 16:399-406.
36. Botteman MF, Hay JW, Luo MP, Curry AS,Wong RL, van Hout BA. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. Rheumatology (Oxford) 2007; 46:1320-1328.